EC
ORGO icon

EntryPoint Capital’s Organogenesis Holdings ORGO Stock Holding History

EntryPoint Capital’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,988
Closed -$166K – 878
2025
Q4 		$166K Buy
+31,988
New +$155K 0.06% 580

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

EntryPoint Capital's ORGO Position: Q1 2026 in Review

EntryPoint Capital sold out of Organogenesis Holdings (ORGO) in Q1 2026, closing a stake of 31,988 shares — an estimated $166K sold.

EntryPoint Capital first reported a position in ORGO in Q4 2025 and held it in 1 quarter. The position peaked at $166K in Q4 2025. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • EntryPoint Capital reported no remaining Organogenesis Holdings position as of Q1 2026 after selling out during the quarter.
  • EntryPoint Capital sold 31,988 Organogenesis Holdings shares in Q1 2026, an estimated $166K.
  • EntryPoint Capital first reported a position in Organogenesis Holdings in Q4 2025 and held it in 1 quarter.
  • EntryPoint Capital's Organogenesis Holdings position peaked at $166K in Q4 2025.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.